What happens after fingolimod discontinuation? A multicentre real-life experience.
Doriana LandiAlessio SignoriMaria CellerinoGiuseppe FenuCarolina Gabri NicolettiMarta PonzanoElisabetta MancusoMarzia FronzaMaria Elena RicchiutoGiacomo BoffaMatilde IngleseGirolama Alessandra MarfiaEleonora CoccoJessica FrauPublished in: Journal of neurology (2021)
The main reason for the discontinuation of fingolimod was inefficacy. One-third of the patients had a relapse during the year after discontinuation, 15% experienced a severe reactivation, and approximately 50% of patients with available MRI scan had new/enhancing lesions. The risk factors for disease activity after discontinuation were low lymphocyte count and younger age.
Keyphrases
- disease activity
- multiple sclerosis
- rheumatoid arthritis
- end stage renal disease
- systemic lupus erythematosus
- newly diagnosed
- ejection fraction
- rheumatoid arthritis patients
- computed tomography
- chronic kidney disease
- ankylosing spondylitis
- magnetic resonance imaging
- clinical trial
- peritoneal dialysis
- peripheral blood
- prognostic factors
- cross sectional